EE200200127A - Taksaanide toimetamine katioonsete liposoomidega angiogeensete veresoonte piirkonda - Google Patents

Taksaanide toimetamine katioonsete liposoomidega angiogeensete veresoonte piirkonda

Info

Publication number
EE200200127A
EE200200127A EEP200200127A EEP200200127A EE200200127A EE 200200127 A EE200200127 A EE 200200127A EE P200200127 A EEP200200127 A EE P200200127A EE P200200127 A EEP200200127 A EE P200200127A EE 200200127 A EE200200127 A EE 200200127A
Authority
EE
Estonia
Prior art keywords
cationic liposomes
taxanes
delivering
blood vessels
angiogenic blood
Prior art date
Application number
EEP200200127A
Other languages
English (en)
Inventor
M. Mcdonald Donald
W. Mclean John
Gavin Thurston O.
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of EE200200127A publication Critical patent/EE200200127A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EEP200200127A 1999-09-09 2000-09-08 Taksaanide toimetamine katioonsete liposoomidega angiogeensete veresoonte piirkonda EE200200127A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39297699A 1999-09-09 1999-09-09
PCT/US2000/024579 WO2001017508A1 (en) 1999-09-09 2000-09-08 Cationic liposome delivery of taxanes to angiogenic blood vessels

Publications (1)

Publication Number Publication Date
EE200200127A true EE200200127A (et) 2003-04-15

Family

ID=23552795

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200127A EE200200127A (et) 1999-09-09 2000-09-08 Taksaanide toimetamine katioonsete liposoomidega angiogeensete veresoonte piirkonda

Country Status (21)

Country Link
US (1) US20100226970A1 (et)
EP (1) EP1210065B1 (et)
JP (2) JP4848113B2 (et)
KR (1) KR100591767B1 (et)
CN (1) CN1235567C (et)
AT (1) ATE324867T1 (et)
AU (1) AU782714B2 (et)
BR (1) BR0013866A (et)
CA (1) CA2383412C (et)
CZ (1) CZ2002850A3 (et)
DE (1) DE60027730T2 (et)
EA (1) EA005923B1 (et)
EE (1) EE200200127A (et)
ES (1) ES2258471T3 (et)
HK (1) HK1046506B (et)
HU (1) HUP0202669A3 (et)
IL (2) IL148372A0 (et)
MX (1) MXPA02002579A (et)
PL (1) PL203128B1 (et)
WO (1) WO2001017508A1 (et)
ZA (1) ZA200201555B (et)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6627201A (en) * 2000-05-03 2001-11-12 Mbt Munich Biotechnology Gmbh Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
ES2272768T3 (es) * 2001-10-03 2007-05-01 Celator Pharmaceuticals Inc Composiciones para la administracion de combinaciones de farmacos.
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2484761C (en) 2002-05-24 2010-11-09 Angiotech International Ag Compositions and methods for coating medical implants
WO2004002455A1 (en) * 2002-06-26 2004-01-08 Medigene Oncology Gmbh Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system
EP1374864A1 (en) * 2002-06-26 2004-01-02 Munich Biotech AG Amphiphilic taxane compositions
JP4975964B2 (ja) 2002-06-26 2012-07-11 メディゲーネ アクチエンゲゼルシャフト 脂肪親和性化合物から成る陽イオン性リポソームの製法
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
WO2004112747A2 (en) 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
EP2286794B8 (en) * 2003-10-15 2016-06-01 SynCore Biotechnology CO., LTD Use of cationic liposomes comprising paclitaxel
JP2007517874A (ja) * 2004-01-16 2007-07-05 バーンズ−ジューイッシュ ホスピタル 標的化アテローム性動脈硬化症治療法
US9233094B2 (en) 2005-05-04 2016-01-12 Medigene Ag Method of administering a cationic liposomal preparation
AU2007228984B2 (en) 2006-03-22 2012-05-03 Syncore Biotechnology Co., Ltd Treatment of triple receptor negative breast cancer
CN101965195A (zh) 2008-03-05 2011-02-02 巴克斯特国际公司 用于药物投送的组合物和方法
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
US9706903B2 (en) 2009-06-18 2017-07-18 Endochoice, Inc. Multiple viewing elements endoscope system with modular imaging units
DE102009032658A1 (de) * 2009-07-09 2011-01-13 Forschungszentrum Jülich GmbH Mischung amphipathischer Moleküle und Verfahren zur Zellmembranmodifikation durch Fusion
KR101007925B1 (ko) * 2009-10-07 2011-01-14 건일제약 주식회사 경구용 지질 나노입자 및 그의 제조방법
IL266198B2 (en) * 2016-10-28 2023-11-01 Servier Lab Liposomal formulation for use in cancer treatment
KR102250123B1 (ko) 2019-11-25 2021-05-10 주식회사 현대케피코 무단 변속기의 제한 목표 기어비 학습 방법
KR102261482B1 (ko) 2019-12-10 2021-06-07 주식회사 현대케피코 무단 변속기의 킥다운 시프트 직후 구동 풀리 제어 압력 보정 방법 및 장치

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5092885A (en) * 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE69114782T2 (de) * 1990-08-08 1996-04-18 Takeda Chemical Industries Ltd Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff.
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
DE69329073T2 (de) * 1992-03-23 2001-01-18 Georgetown University, Washington In liposomen verkapseltes taxol und verwendungsverfahren
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
WO1994026254A1 (en) * 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation of taxol into liposomes and gels
EP0982302B1 (en) * 1993-06-11 2004-04-14 PHARMACIA & UPJOHN COMPANY Delta 6,7-taxols antineoplastic use and pharmaceutical compositions containing them
ES2255477T5 (es) * 1993-07-29 2010-04-08 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Uso de paclitaxel y sus derivados en la fabricacion de un medicamento para el tratamiento de reestenosis.
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5641755A (en) * 1994-02-04 1997-06-24 Arch Development Corp. Regulation of x-ray mediated gene expression
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5512294A (en) * 1994-08-05 1996-04-30 Li; King C. Targeted polymerized liposome contrast agents
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
DE19605274A1 (de) * 1996-02-13 1997-08-14 Hoechst Ag Nukleinsäurekonstrukte für die zellzyklusregulierte Expression von Genen, derartige Konstrukte enthaltende Zellen sowie deren Verwendung zur Herstellung von Heilmitteln
US5977163A (en) * 1996-03-12 1999-11-02 Pg-Txl Company, L. P. Water soluble paclitaxel prodrugs
US5935937A (en) * 1996-06-19 1999-08-10 Fox Chase Cancer Center Compositions and methods for inducing apoptosis
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
AU5646300A (en) * 1999-02-10 2000-08-29 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of stimulating angiogenesis
ES2358416T3 (es) * 2001-10-30 2011-05-10 Novartis Ag Formulaciones de liberación prolongada de iloperidona y polímero en forma de estrella.

Also Published As

Publication number Publication date
CN1235567C (zh) 2006-01-11
BR0013866A (pt) 2002-05-14
EP1210065B1 (en) 2006-05-03
HK1046506B (en) 2006-08-25
EP1210065A4 (en) 2004-04-28
WO2001017508A9 (en) 2002-10-03
ATE324867T1 (de) 2006-06-15
PL354721A1 (en) 2004-02-09
KR20030038530A (ko) 2003-05-16
DE60027730T2 (de) 2007-03-29
HUP0202669A2 (hu) 2004-05-28
CN1378443A (zh) 2002-11-06
WO2001017508A1 (en) 2001-03-15
JP2003514768A (ja) 2003-04-22
KR100591767B1 (ko) 2006-06-23
MXPA02002579A (es) 2003-10-14
CA2383412A1 (en) 2001-03-15
AU7122900A (en) 2001-04-10
ES2258471T3 (es) 2006-09-01
EA200200229A1 (ru) 2003-06-26
JP2010280667A (ja) 2010-12-16
HUP0202669A3 (en) 2004-06-28
CA2383412C (en) 2010-02-02
IL148372A (en) 2007-09-20
JP4848113B2 (ja) 2011-12-28
PL203128B1 (pl) 2009-08-31
IL148372A0 (en) 2002-09-12
AU782714B2 (en) 2005-08-25
CZ2002850A3 (cs) 2003-04-16
DE60027730D1 (de) 2006-06-08
EA005923B1 (ru) 2005-08-25
ZA200201555B (en) 2003-04-30
EP1210065A1 (en) 2002-06-05
US20100226970A1 (en) 2010-09-09
HK1046506A1 (en) 2003-01-17

Similar Documents

Publication Publication Date Title
EP1210065A4 (en) ADMINISTRATION OF TAXANES TO ANGIOGENIC BLOOD VESSELS BY CATIONIC LIPOSOMES
NO994413L (no) Kationiske lipidblandinger mÕlsökende angiogene endotelceller
BRPI0113477B8 (pt) proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula
DK1093383T3 (da) Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel
DE60044084D1 (de) Vorrichtungen zur vergrösserten penetration von mikronadeln in biologischen hautschichten
ATE386127T1 (de) Verbesserung der immunantwort als anwendung in impfstoff und gentherapie
ATE445417T1 (de) Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
DE69723057D1 (de) Nukleosid analogen
WO2003059436A3 (en) Compositions and methods for promoting myocardial and peripheral angiogenesis
IT8619961A0 (it) Supporto per prodotti da cucire per la cucitura della zona di punta di cravatte.
DE69130569D1 (de) Mit psoralen konjugierte methylphosphonat-oligonukleotide als therapeutische wirkstoffe für chronische myologene leukämie
Enns et al. The transferrin receptor
Bielawski et al. Small‐Molecule based Delivery Systems for Alkylating Antineoplastic Compounds
DE60035687D1 (de) Bipolare lipide und ihre verwendung zum transport bioaktiver substanzen
NO20020604D0 (no) Fremgangsmåte for avlevering av terapeutiske midler ved bruk av en dekstrinlösning
National Research Council et al. Addressing the nation's changing needs for biomedical and behavioral scientists
WO2005026206A3 (en) Vegf-induced genes and their therapeutic use
Moon et al. Modification of biomaterials with ephrins and Eph ligands for angiogenic applications
Wu et al. Effects of blood shear flows on liposome binding and uptake to tumor vascular endothelial cells
BR0002581A (pt) Sistema de condução espaldeira
Stojanović et al. Knockdown of integrin αv in human triple-negative breast carcinoma cell lines alters sensitivity to anticancer drugs and inhibits migration
Sidhu et al. Erratum: X chromosome inactivation: heterogeneity of heterochromatin
Tawa et al. P248 ROLES OF ENDOTHELIAL RAP1 SMALL G PROTEIN AND AFADIN IN VEGF-AND S1P-INDUCED ANGIOGENESIS
IT246835Y1 (it) Struttura di supporto per contenitori particolarmente di prodotti incarta , in foglio e simili